Treating tislelizumab‐induced ulcerative lichenoid drug eruption with baricitinib in a patient with lung cancer [PDF]
Jiaqi Lv +5 more
openalex +1 more source
Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami +6 more
wiley +1 more source
Paradoxical lichenoid drug eruption following dupilumab use for atopic dermatitis: A case report. [PDF]
Gandhi M, Vanderbeck K, Giroux L.
europepmc +1 more source
paclitaxel-induced fixed drug eruption: a rare adverse drug reaction case report [PDF]
Rithunandana Sreeja +3 more
openalex +1 more source
Fixed drug eruption due to foscarnet. [PDF]
G M Connolly, Brian Gazzard, D A Hawkins
openalex +1 more source
Fixed drug eruption misdiagnosed as herpes simplex virus infection. [PDF]
Moschella A, Gifford F.
europepmc +1 more source
Dermatology 2.0: Precision medicine for inflammatory skin diseases
Digital immune mapping of transcriptomics profiles from inflammatory skin disease biopsies enables precise molecular diagnosis, quantification of immune modules and personalized therapy selection by matching dominant immune signatures to targeted treatments.
Jeremy Di Domizio +4 more
wiley +1 more source
Candesartan-Associated Lichenoid Drug Eruption. [PDF]
Iijima K, Mima Y.
europepmc +1 more source
Drug points: Psoriasiform eruptions associated with penicillamine [PDF]
Jennifer Forgie, A. S Highet
openalex +1 more source
Cell Therapy for Periodontal, Soft‐Tissue, and Craniofacial Regeneration
The clinical translation of mesenchymal stem/stromal cells (MSCs) represents a major advancement in dentistry, especially for periodontal, soft‐tissue, and craniofacial regeneration. However, several challenges remain to be addressed, including the absence of standardised protocols, limited scalability, regulatory hurdles, a lack of well‐controlled ...
Kamal Mustafa +5 more
wiley +1 more source

